Skip to content

Xencor XNCR Accounts Receivable

Accounts Receivable at other companies

Amgen logo
AmgenAMGN
$9.14B+12.4%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$5.73B+3.1%
Janux Therapeutics logo
Janux TherapeuticsJANX
$35M
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$39.16M-38.4%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$25.75M+44.0%
Absci Corporation logo
Absci CorporationABSI
$100K-92.8%

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+76.3%
Enterprise value$1.23B+55.9%
P/S11×+6.2×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's accounts receivable?
Xencor (XNCR) reported accounts receivable of $12M in Q1 2026.
How has Xencor's accounts receivable changed year-over-year?
Xencor's accounts receivable decreased by 68.2% year-over-year, from $37.79M to $12M.
What is the long-term trend for Xencor's accounts receivable?
Over 5 years (2020 to 2025), Xencor's accounts receivable has grown at a 20.7% compound annual growth rate (CAGR), from $11.44M to $29.3M.
What does accounts receivable mean?
Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.